Cell-based therapy using miR-302-367 expressing cells represses glioblastoma growth

Journal Article (2017)
Author(s)

M. Fareh (Kavli institute of nanoscience Delft, Univ. Nice Sophia Antipolis, TU Delft - BN/Chirlmin Joo Lab)

Fabien Almairac (Univ. Nice Sophia Antipolis, Hôpital Pasteur)

Laurent Turchi (Univ. Nice Sophia Antipolis)

Fanny Burel-Vandenbos (Univ. Nice Sophia Antipolis, Hôpital Pasteur)

Philippe Paquis (Hôpital Pasteur, Univ. Nice Sophia Antipolis)

Denys Fontaine (Hôpital Pasteur)

Sandra Lacas-Gervais (Univ. Nice Sophia Antipolis)

Marie Pierre Junier (Universite Pierre et Marie Curie (UPMC), Institut universitaire de technologie IBPS)

Hervé Chneiweiss (Universite Pierre et Marie Curie (UPMC), Institut universitaire de technologie IBPS)

Thierry Virolle (Univ. Nice Sophia Antipolis)

Research Group
BN/Chirlmin Joo Lab
Copyright
© 2017 M. Fareh, Fabien Almairac, Laurent Turchi, Fanny Burel-Vandenbos, Philippe Paquis, Denys Fontaine, Sandra Lacas-Gervais, Marie Pierre Junier, Hervé Chneiweiss, Thierry Virolle
DOI related publication
https://doi.org/10.1038/cddis.2017.117
More Info
expand_more
Publication Year
2017
Language
English
Copyright
© 2017 M. Fareh, Fabien Almairac, Laurent Turchi, Fanny Burel-Vandenbos, Philippe Paquis, Denys Fontaine, Sandra Lacas-Gervais, Marie Pierre Junier, Hervé Chneiweiss, Thierry Virolle
Research Group
BN/Chirlmin Joo Lab
Issue number
3
Volume number
8
Reuse Rights

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Abstract

Glioblastomas are incurable primary brain tumors that affect patients of all ages. The aggressiveness of this cancer has been attributed in part to the persistence of treatment-resistant glioblastoma stem-like cells. We have previously discovered the tumor-suppressor properties of the microRNA cluster miR-302-367, representing a potential treatment for glioblastoma. Here, we attempted to develop a cell-based therapy by taking advantage of the capability of glioma cells to secrete exosomes that enclose small RNA molecules. We engineered primary glioma cells to stably express the miR-302-367. Remarkably, these cells altered, in a paracrine-dependent manner, the expression of stemness markers, the proliferation and the tumorigenicity of neighboring glioblastoma cells. Further characterization of the secretome derived from miR-302-367 expressing cells showed that a large amount of miR-302-367 was enclosed in exosomes, which were internalized by the neighboring glioblastoma cells. This miR-302-367 cell-To-cell transfer resulted in the inhibition of its targets such as CXCR4/SDF1, SHH, cyclin D, cyclin A and E2F1. Orthotopic xenograft of miR-302-367-expressing cells together with glioblastoma stem-like cells efficiently altered the tumor development in mice brain.